Abstract
Study question Are vertebrate NANOS proteins associated with human fertility, and can a rapid in vivo assay in zebrafish be established to evaluate the biological activity of human NANOS variants?
Summary answer Combining a rapid in vivo assay we developed for Nanos protein activity and patient-derived genetic data, we identified NANOS variants that could contribute to male infertility.
What is known already Male infertility affects approximately 17% of the population, but linking specific gene variants to this condition remains challenging. NANOS proteins are essential regulators of germ cell development in different model organisms; however, a rapid and robust in vivo assay for evaluating their activity in the context of human male infertility is currently lacking.
Study design, size, duration Exome/genome data from 3,338 men included in the Male Reproductive Genomics (MERGE) cohort were examined in this study. Of these, 2038 men showed severely impaired spermatogenesis but were otherwise healthy. Ninety-Six men with intact spermatogenesis were included in the study as controls. Additionally, the study included a targeted analysis of NANOS variants in 44 patients from the IMIGC cohort.
Participants/materials, setting, methods The exome/genome data were screened for rare, stop-gain, frameshift, splice site, as well as missense variants in NANOS1, NANOS2, and NANOS3. Human amino acid substitutions were introduced at the corresponding positions in the zebrafish proteins. Ectopic co-expression of wild-type Dnd1 and Nanos3 in zebrafish embryos induces a germ cell-like fate in somatic cells, resulting in severe developmental defects and embryonic lethality. Based on this principle, we established a rapid in vivo assay in which wild-type Dnd1 was co-expressed with wild-type or variant Nanos2 and Nanos3 proteins in live zebrafish embryos, expecting early embryonic death if a variant protein is functional. This assay was used to evaluate the activity of NANOS2 and NANOS3 variants identified in men with infertility.
Main results and the role of chance In human exome/genome sequencing data, we identified one heterozygous missense variant in NANOS2 and two heterozygous missense variants in NANOS3. The function of the variants was examined in the zebrafish using the in vivo assay we developed. Co-expression of wild-type Dnd1 with selected Nanos2 or Nanos3 variants identified in infertile men resulted in defects in induction of the germ cell-like phenotype, demonstrating the power of the biological readout for evaluating the potential effects of patient-derived variants on NANOS protein activity. Together, our analysis enabled the evaluation of single nucleotide variants, whose impact on protein function is difficult to predict, and allowed us to distinguish variants with little or no effect on protein function from those that strongly reduce activity and may potentially contribute to infertility.
Limitations, reasons for caution The assay requires access to zebrafish embryos and basic imaging equipment. Although the functional conservation of NANOS proteins between zebrafish and humans is supported by previous studies, species-specific differences may influence protein activity. Therefore, the zebrafish assay should be considered one component of a broader framework for evaluating NANOS variants as contributing factor for infertility.
Wider implications of the findings Using NANOS2 and NANOS3 as examples, we demonstrate that integrating clinical genetic data with functional cell and developmental biology can help establish links between candidate disease genes and human fertility. This strategy may apply to other germline-specific genes whose ectopic expression produces measurable developmental phenotypes in zebrafish embryos.
Study funding/competing interest(s) We acknowledge the support from the Spanish Ministry of Health Instituto Carlos III-FIS FONDOS FEDER (grant number PI23/00425), the German Research Foundation (DFG) grants to E.R. (RA 863/17-1, RA 863/18-1), to E.R., C.F., and F.T. (Clinical Research Unit ‘Male Germ Cells’, CRU 326, project number 329621271), to S.K., C.F., and F.T. (Collaborative Research Centre ‘Reproduction.MS’, SFB 1748, project number 549467913), the Federal Ministry of Research, Technology and Space (BMFTR) Junior Scientist Research Centre ‘ReproTrack.MS’ to S.K. and F.T. (project number 01GR2303), and funding from the Medical Faculty of the University of Münster.
The authors declare no competing interests
Trial registration number N/A.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All men provided written informed consent, and the study was approved by the Ethics Committee of the Medical Faculty Muenster and the Aerztekammer Westfalen-Lippe (2010-578-f-S, 2026-431-f-S) in accordance with the Helsinki Declaration of 1975. Targeted look up for NANOS1, NANOS2, and NANOS3 gene variants was performed among the members of IMIGC and subject NOA5 belonged to a cohort of 44 patients who underwent Whole Genome Sequencing (WGS) from the Fundacio Puigvert, Barcelona, Spain; all patients signed an informed consent form and the study was approved by the local Ethical Committee of the Fundacio Puigvert, Barcelona (PI23/00425).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors





